Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

• William L Redmond,
• Walter J Urba,
• John Cha,
• Yoshinobu Koguchi,
• Brendan D Curti,
• Noriko Iwamoto,
• Takashi Shimada,
• Shu-Ching Chang,
• Brian D Piening

Affiliations

William L Redmond

Earle A. Chiles Research Institute, Portland, Oregon, USA

Walter J Urba

Providence Cancer Institute, Portland, Oregon, USA

John Cha

1Providence Cancer Institute, Portland, OR, USA

Yoshinobu Koguchi

1Providence Cancer Institute, Portland, OR, USA

Brendan D Curti

Aff1 grid.415286.cEarle A. Chiles Research Institute Portland OR USA

Noriko Iwamoto

2Shimadzu Scientific Instruments, Bothell, WA, USA

Takashi Shimada

2Shimadzu Scientific Instruments, Bothell, WA, USA

Shu-Ching Chang

3Providence St. Joseph Health, Portland, OR, USA

Brian D Piening

Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA